Emicizumab Changes the Lifestyle of Patients with Hemophilia A

Introduction

Emicizumab, a bispecific antibody that mimics the function of FVIII as a cofactor, has convincingly changed medical care for many individuals with hemophilia A (HA) since its introduction into clinical practice, for both those with and without inhibitors. It has unequivocally facilitated the administration of prophylaxis, which is very effective. One of the remaining questions is whether it has truly changed the lifestyle of these patients.

Observational Data from One Center

Data from the University of Colorado evaluated individuals with HA who were treated with emicizumab for ≥ 1 month. The research was conducted via telephone, lasting approximately 5–10 minutes, and focused on side effects, bleeding, physical activity, medication, and travel. Adults or parents of children were interviewed.

A total of 66 people were surveyed. Responses were available from 47 patients aged 6 months to 79 years (average age 18.3 years, median 13.1 years) who had been treated with emicizumab for 1.2–10.5 months.

The administration of emicizumab was associated with improved joint health (73%; no one reported worsening), less need for analgesics (65%), reduced absenteeism from work or school, and increased physical activity (55%; no one reported decreased physical activity). Up to a quarter of people reported trying new physical activities after changing treatment. Several patients (17%) admitted to missing a dose of emicizumab, indicating that adherence was not entirely perfect.

Conclusion

Data from real-world clinical practice support the positive impact of emicizumab treatment in individuals with hemophilia, allowing for better social engagement and increased physical activity. However, it is also important to note that patient adherence over time was not always perfect, and this should be a focus as well.

(eza)

Source: Chan A., Warren B., Ng C. et al. Influence of emicizumab on patient lifestyle at the University of Colorado. MED-PP-010 (616). WFH Kuala Lumpur, 2020 Jun.